ID

18444

Description

Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00491127

Link

https://clinicaltrials.gov/show/NCT00491127

Keywords

  1. 11/5/16 11/5/16 -
Uploaded on

November 5, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Hodgkin's Lymphoma NCT00491127

Eligibility Non-Hodgkin's Lymphoma NCT00491127

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
the patients must have a histological diagnosis of aggressive non-hodgkin’s lymphoma including the following sub-categories of the who classification:
Description

Aggressive Non-Hodgkin Lymphoma | WHO tumor classification

Data type

boolean

Alias
UMLS CUI [1]
C1332225
UMLS CUI [2]
C1301142
diffuse large b-cell lymphoma and its variants (immunoblastic, burkitt-like, sclerosis of mediastinum, large b-cell malt, rich in t-cells and anaplastic b-cell lymphoma)
Description

Diffuse Large B-Cell Lymphoma | Immunoblastic Large-Cell Lymphoma | Burkitt-like lymphoma | Sclerosis Mediastinum | Mucosa-Associated Lymphoid Tissue Lymphoma | T-Cell Lymphoma | Anaplastic large B-cell lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C0079744
UMLS CUI [2]
C0079746
UMLS CUI [3]
C1368771
UMLS CUI [4,1]
C0036429
UMLS CUI [4,2]
C0025066
UMLS CUI [5]
C0242647
UMLS CUI [6]
C0079772
UMLS CUI [7]
C1321546
peripheral t-cell lymphoma
Description

Peripheral T-Cell Lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C0079774
anaplastic lymphoma of large t-cells /null cells
Description

Large cell anaplastic lymphoma T cell and Null cell type

Data type

boolean

Alias
UMLS CUI [1]
C3838707
patients are eligible if they have documented evidence of progression after prior first-line chemotherapy containing anthracyclines associated or not with rituximab. patients with refractory disease to first line of treatment are also eligible.
Description

chemotherapeutics regimen first line of treatment | Anthracyclines | rituximab | Disease Progression Evidence of | Refractory Disease

Data type

boolean

Alias
UMLS CUI [1]
C2045825
UMLS CUI [2]
C0282564
UMLS CUI [3]
C0393022
UMLS CUI [4,1]
C0242656
UMLS CUI [4,2]
C0332120
UMLS CUI [5]
C1514815
ecog ps (performance status) less than or equal to 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
presence of bidimensionally measurable disease in accordance with who criteria.
Description

Measurable Disease 2-Dimensional

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1705052
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
involvement of the cns.
Description

Central Nervous System Involvement

Data type

boolean

Alias
UMLS CUI [1]
C4050309
any medical condition which contraindicates the degree of hydration required for the safe use of cisplatin.
Description

Medical condition Contraindication Cisplatin

Data type

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C1301624
UMLS CUI [1,3]
C0008838
intermediate degree lymphoma derived from the malignant transformation of a previous low-grade lymphoma.
Description

Intermediate-Grade Lymphoma Derived Malignant lymphoma unclassifiable low grade

Data type

boolean

Alias
UMLS CUI [1,1]
C0079741
UMLS CUI [1,2]
C1441547
UMLS CUI [1,3]
C0854880
active infection (in the opinion of the investigator).
Description

Communicable Disease

Data type

boolean

Alias
UMLS CUI [1]
C0009450

Similar models

Eligibility Non-Hodgkin's Lymphoma NCT00491127

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Aggressive Non-Hodgkin Lymphoma | WHO tumor classification
Item
the patients must have a histological diagnosis of aggressive non-hodgkin’s lymphoma including the following sub-categories of the who classification:
boolean
C1332225 (UMLS CUI [1])
C1301142 (UMLS CUI [2])
Diffuse Large B-Cell Lymphoma | Immunoblastic Large-Cell Lymphoma | Burkitt-like lymphoma | Sclerosis Mediastinum | Mucosa-Associated Lymphoid Tissue Lymphoma | T-Cell Lymphoma | Anaplastic large B-cell lymphoma
Item
diffuse large b-cell lymphoma and its variants (immunoblastic, burkitt-like, sclerosis of mediastinum, large b-cell malt, rich in t-cells and anaplastic b-cell lymphoma)
boolean
C0079744 (UMLS CUI [1])
C0079746 (UMLS CUI [2])
C1368771 (UMLS CUI [3])
C0036429 (UMLS CUI [4,1])
C0025066 (UMLS CUI [4,2])
C0242647 (UMLS CUI [5])
C0079772 (UMLS CUI [6])
C1321546 (UMLS CUI [7])
Peripheral T-Cell Lymphoma
Item
peripheral t-cell lymphoma
boolean
C0079774 (UMLS CUI [1])
Large cell anaplastic lymphoma T cell and Null cell type
Item
anaplastic lymphoma of large t-cells /null cells
boolean
C3838707 (UMLS CUI [1])
chemotherapeutics regimen first line of treatment | Anthracyclines | rituximab | Disease Progression Evidence of | Refractory Disease
Item
patients are eligible if they have documented evidence of progression after prior first-line chemotherapy containing anthracyclines associated or not with rituximab. patients with refractory disease to first line of treatment are also eligible.
boolean
C2045825 (UMLS CUI [1])
C0282564 (UMLS CUI [2])
C0393022 (UMLS CUI [3])
C0242656 (UMLS CUI [4,1])
C0332120 (UMLS CUI [4,2])
C1514815 (UMLS CUI [5])
ECOG performance status
Item
ecog ps (performance status) less than or equal to 2
boolean
C1520224 (UMLS CUI [1])
Measurable Disease 2-Dimensional
Item
presence of bidimensionally measurable disease in accordance with who criteria.
boolean
C1513041 (UMLS CUI [1,1])
C1705052 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Central Nervous System Involvement
Item
involvement of the cns.
boolean
C4050309 (UMLS CUI [1])
Medical condition Contraindication Cisplatin
Item
any medical condition which contraindicates the degree of hydration required for the safe use of cisplatin.
boolean
C3843040 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
C0008838 (UMLS CUI [1,3])
Intermediate-Grade Lymphoma Derived Malignant lymphoma unclassifiable low grade
Item
intermediate degree lymphoma derived from the malignant transformation of a previous low-grade lymphoma.
boolean
C0079741 (UMLS CUI [1,1])
C1441547 (UMLS CUI [1,2])
C0854880 (UMLS CUI [1,3])
Communicable Disease
Item
active infection (in the opinion of the investigator).
boolean
C0009450 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial